MedTrace Logo

Creating Physical Objects With 3D Printers to Stimulate Reminiscing for Memory Loss [2 R44 AG049548-02A1]

NCT03625973 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2022-04-25

No results posted yet for this study

Summary

In 2013 an estimated 5 million people age 65 and older had Alzheimer's disease. Longer life spans and aging baby boomers will cause this number to grow rapidly. More than 50% of residents in assisted living and nursing homes have some form of dementia or cognitive impairment and the number is increasing every day.

As a form of person-centered, non-pharmacological dementia care, Reminiscence Therapy (RT) holds considerable promise. Improvements in mood, quality of life, social interaction, cognition, memory and a reduction in caregiver stress have been noted. This project will develop an operational model for identifying and producing 3D personal objects using 3D printing technology, and deploying them for use in RT. The research also will evaluate the effectiveness of using 3D-printed objects in RT compared to other types of memory stimuli. This novel approach to the "personalization" of reminiscence therapy will result in better social and mental health outcomes for individuals with dementia.

Conditions

Interventions

BEHAVIORAL

3D-RT

Objects printed using 3D printing media will be used as stimuli in Reminiscence Therapy

BEHAVIORAL

RT-Verbal

Verbal cues will be used as stimuli in Reminiscence Therapy

Sponsors & Collaborators

  • St. Louis University

    collaborator OTHER

  • The University of Texas at Arlington

    collaborator OTHER

  • Moai Technologies LLC

    lead OTHER

Principal Investigators

  • Olu Olofinboba, MS · Moai Technologies LLC

  • Marla Berg-Weger, PhD · St. Louis University

  • Keith Anderson, PhD · The University of Texas at Arlington

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-30
Primary Completion
2022-11-30
Completion
2022-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03625973 on ClinicalTrials.gov